# A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted

> **NCT01775189** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 45 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ALO-02 weight-matched placebo
- **DRUG:** crushed ALO-02 30 mg/3.6 mg
- **DRUG:** oxycodone weight-matched placebo
- **DRUG:** crushed oxycodone IR 30 mg

## Key facts

- **NCT ID:** NCT01775189
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2017-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01775189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01775189, "A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01775189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*